Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment
share announcement

Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (26 June 2023) | Viewed by 9899

Special Issue Editors

Dr. Georgios Kokolakis

E-Mail Website
Guest Editor
Psoriasis Research and Treatment Centre, Clinic of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, 10117 Berlin, Germany
Interests: psoriasis; hidradenitis suppurativa; clinical trials; biological therapy; inflammation medicine; interdisciplinary consultation; dermatology; immunology
Dr. Andreas Pinter

E-Mail Website
Guest Editor
Department of Dermatology, Venereology, and Allergology, University Hospital, 60590 Frankfurt am Main, Germany
Interests: immunology; psoriasis; atopic dermatitis; hidradenitis suppurativa; autoimmune diseases; autoinflammatory diseases; dermatosurgery; clinical trials

Special Issue Information

Dear Colleagues,

The better understanding of immunological processes in skin inflammation has revolutionized the therapeutic concepts of not only skin diseases themselves but also comorbid diseases of other organs. The easy approach to the skin and the visibility of its alterations render it an exceptional model to investigate and treat. New classes of targeted therapies, such as biologics or small molecules, have tremendously improved the outcomes of previously poorly treated diseases. Beyond the skin, the majority of these substances have been thereafter applied for the treatment of extra-cutaneous diseases, indicating the importance of extrapolating knowledge to inflammation of other organs.

This Special Issue aims to publish new data on the symptoms, causes, diagnosis and treatment of skin inflammation, in order to better understand diseases and improve clinical practice.

Dr. Georgios Kokolakis
Dr. Andreas Pinter
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin inflammation
  • autoinflammation
  • autoimmunity
  • immunology
  • infectious disease
  • novel therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 1062 KiB  
Article
Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland
by Michał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, Kinga Adamska, Zygmunt Adamski, Maria Czubek, Beata Kręcisz, Elżbieta Kłujszo, Aleksandra Lesiak, Joanna Narbutt, Marcin Noweta, Agnieszka Owczarczyk-Saczonek, Witold Owczarek, Adam Reich, Dominik Samotij, Aleksandra Siekierko, Justyna Szczęch, Irena Walecka, Piotr Ciechanowicz, Anna Woźniacka, Agata Liszewska and Dorota Krasowskaadd Show full author list remove Hide full author list
J. Clin. Med. 2023, 12(4), 1675; https://doi.org/10.3390/jcm12041675 - 20 Feb 2023
Cited by 5 | Viewed by 2184
Abstract
The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis [...] Read more.
The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient’s age and duration of psoriasis at several timepoints throughout the observation period. Full article
(This article belongs to the Special Issue Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

12 pages, 1531 KiB  
Article
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study
by Sebastian Kiefer, Anke König, Viviane Gerger, Christine Rummenigge, Anne Christine Müller, Thomas Jung, Alexandra Frank, Georgios Tassopoulos, Emilie Laurent, Roland Kaufmann and Andreas Pinter
J. Clin. Med. 2023, 12(3), 1175; https://doi.org/10.3390/jcm12031175 - 1 Feb 2023
Cited by 4 | Viewed by 3171
Abstract
For the treatment of moderate-to-severe atopic dermatitis in children and adolescents, the monoclonal antibody dupilumab and the selective JAK-1 inhibitor upadacitinib are two modern systemic therapies approved for long-term treatment. Both drugs have demonstrated high efficacy in randomized controlled trials, although evidence from [...] Read more.
For the treatment of moderate-to-severe atopic dermatitis in children and adolescents, the monoclonal antibody dupilumab and the selective JAK-1 inhibitor upadacitinib are two modern systemic therapies approved for long-term treatment. Both drugs have demonstrated high efficacy in randomized controlled trials, although evidence from real-world data in the pediatric population is limited. In a prospective analysis over 24 weeks, we investigated the efficacy, safety and treatment satisfaction of both systemic therapies in 23 patients (16 patients treated with dupilumab; 7 patients treated with upadacitinib). The median age of the patients was 16 years, with a median EASI of 18.8. A significant improvement in the EASI, VAS-itch, CDLQI, POEM and DFIQ from baseline to week 24 was demonstrated for both treatment options. No significant difference was observed between dupilumab and upadacitinib in any of the assessed scores. Less adverse events were recorded in the real-world setting compared with clinical trials. Our results confirm the efficacy and safety of dupilumab and upadacitinib as equivalent treatment options in children and adolescents in a real-world setting. Full article
(This article belongs to the Special Issue Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

13 pages, 673 KiB  
Article
Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea
by Paulina Szczepanik-Kułak, Małgorzata Michalska-Jakubus, Małgorzata Kowal and Dorota Krasowska
J. Clin. Med. 2022, 11(21), 6375; https://doi.org/10.3390/jcm11216375 - 28 Oct 2022
Cited by 3 | Viewed by 1497
Abstract
Morphea/localized scleroderma (LoS) represents an inflammatory-sclerotic skin disease, the pathogenesis of which is not fully understood. Given the important role of IL-1 family cytokines in the development and therapy of inflammatory diseases, including systemic sclerosis, we analyzed the clinical significance of serum levels [...] Read more.
Morphea/localized scleroderma (LoS) represents an inflammatory-sclerotic skin disease, the pathogenesis of which is not fully understood. Given the important role of IL-1 family cytokines in the development and therapy of inflammatory diseases, including systemic sclerosis, we analyzed the clinical significance of serum levels of selected IL-1 family cytokines (IL-1α, IL-1β, IL-18, IL-33, IL-37 and IL-38) in LoS patients (n = 30) using the standardized disease assessment tools and comparison to healthy controls (n = 28). We also compared the pre- and post-treatment concentrations, i.e., before and after systemic (glucocorticosteroids and/or methotrexate) and/or topical (topical glucocorticosteroids and/or calcineurin inhibitors). Our findings did not reveal significant differences in baseline IL-1α, IL-1β, IL-18, IL-33, IL-37 and IL-38 levels between LoS group and HCs; however, after treatment, there were marked changes in concentrations of IL-1α and IL-33 within LoS group as well as in comparison to HCs. We also found significant negative correlations between PGA-A and IL-1α concentration as well as between mLoSSI and IL-1α after treatment. Furthermore, we showed an inverse correlation of baseline IL-1β levels with mLoSSI scores of borderline significance. We believe that IL-1α and IL-33, as well as Il-1β, may be potential mediators and targets of interest in LoS. Full article
(This article belongs to the Special Issue Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 1032 KiB  
Brief Report
The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus—A Pilot Study
by Zsófia Király, Eszter Nagy, Laura Bokor, Anikó Kovács, Márta Marschalkó and Bernadett Hidvégi
J. Clin. Med. 2023, 12(17), 5648; https://doi.org/10.3390/jcm12175648 - 30 Aug 2023
Viewed by 2251
Abstract
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with various clinical forms, including the subtypes of discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). The altered function of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) axis in [...] Read more.
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with various clinical forms, including the subtypes of discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). The altered function of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) axis in CLE pathogenesis has been suggested. Here, the soluble forms of PD-1 (sPD-1) and PD-L1 (sPD-L1) were explored in untreated DLE and SCLE. Levels of sPD-1 and sPD-L1 were determined by enzyme-linked immunosorbent assay in serums of 21 DLE, 18 SCLE, 13 systemic lupus erythematosus (SLE) patients and 20 healthy controls (HCs). Differences between patient groups and HCs, and the association between clinical activity of skin symptoms and sPD-1/sPD-L1 levels were analyzed with Mann–Whitney U-test and Spearmann’s correlation. Regarding sPD-1 levels, no statistically significant differences were found between DLE and SCLE groups, nor compared to HCs. As for sPD-L1, a significantly lower level was found in the DLE group compared to the SCLE and HC groups (p = 0.027 and p = 0.009, respectively). In SLE, significantly higher sPD-1 was found compared to HCs (p = 0.002). No association between skin symptom activity and sPD-1/sPD-L1 levels was found in CLE. Alterations of the inhibitory effect of sPD-L1 on T-cell activity might elucidate the differences between DLE and SCLE. Full article
(This article belongs to the Special Issue Skin Inflammation: Symptoms, Causes, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop